702 related articles for article (PubMed ID: 29580257)
1. Gut microbiome modulates efficacy of immune checkpoint inhibitors.
Yi M; Yu S; Qin S; Liu Q; Xu H; Zhao W; Chu Q; Wu K
J Hematol Oncol; 2018 Mar; 11(1):47. PubMed ID: 29580257
[TBL] [Abstract][Full Text] [Related]
2. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Routy B; Le Chatelier E; Derosa L; Duong CPM; Alou MT; Daillère R; Fluckiger A; Messaoudene M; Rauber C; Roberti MP; Fidelle M; Flament C; Poirier-Colame V; Opolon P; Klein C; Iribarren K; Mondragón L; Jacquelot N; Qu B; Ferrere G; Clémenson C; Mezquita L; Masip JR; Naltet C; Brosseau S; Kaderbhai C; Richard C; Rizvi H; Levenez F; Galleron N; Quinquis B; Pons N; Ryffel B; Minard-Colin V; Gonin P; Soria JC; Deutsch E; Loriot Y; Ghiringhelli F; Zalcman G; Goldwasser F; Escudier B; Hellmann MD; Eggermont A; Raoult D; Albiges L; Kroemer G; Zitvogel L
Science; 2018 Jan; 359(6371):91-97. PubMed ID: 29097494
[TBL] [Abstract][Full Text] [Related]
3. The intimate relationship between gut microbiota and cancer immunotherapy.
Elkrief A; Derosa L; Zitvogel L; Kroemer G; Routy B
Gut Microbes; 2019; 10(3):424-428. PubMed ID: 30339501
[TBL] [Abstract][Full Text] [Related]
4. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
[TBL] [Abstract][Full Text] [Related]
5. Immunological and clinical implications of immune checkpoint blockade in human cancer.
Kim HD; Park SH
Arch Pharm Res; 2019 Jul; 42(7):567-581. PubMed ID: 30843144
[TBL] [Abstract][Full Text] [Related]
6. The gut microbiota and immune checkpoint inhibitors.
Humphries A; Daud A
Hum Vaccin Immunother; 2018; 14(9):2178-2182. PubMed ID: 29494275
[TBL] [Abstract][Full Text] [Related]
7. A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer.
Kim E; Ahn H; Park H
Mamm Genome; 2021 Aug; 32(4):223-231. PubMed ID: 33783613
[TBL] [Abstract][Full Text] [Related]
8. Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy.
Huang J; Jiang Z; Wang Y; Fan X; Cai J; Yao X; Liu L; Huang J; He J; Xie C; Wu Q; Cao Y; Leung EL
Curr Opin Pharmacol; 2020 Oct; 54():1-10. PubMed ID: 32619934
[TBL] [Abstract][Full Text] [Related]
9. The role of the sex hormone-gut microbiome axis in tumor immunotherapy.
Wang L; Tang L; Zhai D; Song M; Li W; Xu S; Jiang S; Meng H; Liang J; Wang Y; Zhang B
Gut Microbes; 2023; 15(1):2185035. PubMed ID: 36880651
[TBL] [Abstract][Full Text] [Related]
10. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
Gopalakrishnan V; Spencer CN; Nezi L; Reuben A; Andrews MC; Karpinets TV; Prieto PA; Vicente D; Hoffman K; Wei SC; Cogdill AP; Zhao L; Hudgens CW; Hutchinson DS; Manzo T; Petaccia de Macedo M; Cotechini T; Kumar T; Chen WS; Reddy SM; Szczepaniak Sloane R; Galloway-Pena J; Jiang H; Chen PL; Shpall EJ; Rezvani K; Alousi AM; Chemaly RF; Shelburne S; Vence LM; Okhuysen PC; Jensen VB; Swennes AG; McAllister F; Marcelo Riquelme Sanchez E; Zhang Y; Le Chatelier E; Zitvogel L; Pons N; Austin-Breneman JL; Haydu LE; Burton EM; Gardner JM; Sirmans E; Hu J; Lazar AJ; Tsujikawa T; Diab A; Tawbi H; Glitza IC; Hwu WJ; Patel SP; Woodman SE; Amaria RN; Davies MA; Gershenwald JE; Hwu P; Lee JE; Zhang J; Coussens LM; Cooper ZA; Futreal PA; Daniel CR; Ajami NJ; Petrosino JF; Tetzlaff MT; Sharma P; Allison JP; Jenq RR; Wargo JA
Science; 2018 Jan; 359(6371):97-103. PubMed ID: 29097493
[TBL] [Abstract][Full Text] [Related]
11. Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy.
Tian M; Zhang S; Tseng Y; Shen X; Dong L; Xue R
Anticancer Agents Med Chem; 2022; 22(7):1244-1256. PubMed ID: 34229597
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
Front Immunol; 2021; 12():669150. PubMed ID: 34267748
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiome and cancer immunotherapy.
Sun JY; Yin TL; Zhou J; Xu J; Lu XJ
J Cell Physiol; 2020 May; 235(5):4082-4088. PubMed ID: 31663125
[TBL] [Abstract][Full Text] [Related]
14. Gold digging: Searching for gut microbiota that enhances antitumor immunity.
Hou F; Pan Z; Yang R; Zhi F; Bi Y
J Cell Physiol; 2021 Aug; 236(8):5495-5511. PubMed ID: 33452716
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
16. Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review.
Huang C; Li M; Liu B; Zhu H; Dai Q; Fan X; Mehta K; Huang C; Neupane P; Wang F; Sun W; Umar S; Zhong C; Zhang J
Front Oncol; 2021; 11():642110. PubMed ID: 33816289
[No Abstract] [Full Text] [Related]
17. Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy.
Shui L; Yang X; Li J; Yi C; Sun Q; Zhu H
Front Immunol; 2019; 10():2989. PubMed ID: 32010123
[TBL] [Abstract][Full Text] [Related]
18. Possible Biomarkers for Cancer Immunotherapy.
Otoshi T; Nagano T; Tachihara M; Nishimura Y
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31277279
[TBL] [Abstract][Full Text] [Related]
19. Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer.
Katayama Y; Yamada T; Tanimura K; Yoshimura A; Takeda T; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
Thorac Cancer; 2019 Mar; 10(3):526-532. PubMed ID: 30666802
[TBL] [Abstract][Full Text] [Related]
20. The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era.
Spyrou N; Vallianou N; Kadillari J; Dalamaga M
Semin Cancer Biol; 2021 Aug; 73():356-376. PubMed ID: 33989733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
